Ann-Marie Hyatt, MD

Dawes Fretzin Clinical Research Group, LLC
7910 North Shadeland Avenue
Indianapolis, IN 46250
Phone (317) 516-5030
Fax (317) 516-5031
annmariedfcrg@gmail.com

Dawes Fretzin Dermatology Group, LLC
7910 North Shadeland Avenue
Indianapolis, IN 46250
Phone (317) 516-5000
Fax (317) 516-5031

Education

University of Cincinnati (Cincinnati, OH)
Dermatopathology Fellowship, 2010-2011

Indiana University School of Medicine (Indianapolis, IN)
Dermatology Residency, 2006-2010

Indiana University School of Medicine (Indianapolis, IN)
Medical Doctorate, 2002-2006

Kenyon College (Gambier, OH)
Bachelor of Arts Degree in Neuroscience, 1997-2001

Professional Experience

Marian University (Indianapolis, IN)
Clinical Assistant Professor, November 2014-Present

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Sub-Investigator, October 2012-Present

Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Dermatologist, Dermatopathologist, August 2012 – Present

Dermatology Center of Southern Indiana (Bloomington, IN)
Dermatologist, Dermatopathologist, August 2011 – August 2012

Indiana University School of Medicine Dept. of Dermatology (Indianapolis, IN)
Research Assistant, August 2005 – September 2005

Merck Research Laboratories (Philadelphia, PA)
Research Intern, July 2001 – September 2001

Indiana University Institute of Psychiatric Research (Indianapolis, IN)
Research Assistant, May 1998 – August 1998

AHyatt 8/24/22

Honors and Awards

2010 Cleve Francoeur Award – top dermatology resident
2006 Dermatology Student Award – top medical student
2004 Gold Humanism Honor Society – IUSM award for humanism in medicine
2003 Fred E. Gifford Scholarship – IUSM award based on academic standing
2002 Earl C. & Noel S. McBride Scholarship – IUSM
2002 Dr. Primo Andres Cardiology Award – top student in cardiology

Ann-Marie Hyatt, MD

Articles and Publications

Combined Atypical Fibroxanthoma and Acantholytic Squamous Cell Carcinoma – case letter accepted for publication by American Journal of Dermatopathology May 2011

Gatson, N.T., Travers, J.B., Al-Hassani M., Warren, S.J., Hyatt, A.M., Travers, J.B. ***"Progression of Toxic Epidermal Necrolysis After Tanning Bed Exposure."*** Archives of Dermatology 147(6):719-23, 2011.

Travers, J.B., Kozman, A., Mousdicas, N., Saha, C., Landis, M., Al-Hassani, M., Yao, W., Yao, Y., Hyatt, A.M., Sheehan, M.P., Haggstrom, A.N., Kaplan, M.H. ***"Infected Atopic Dermatitis Lesions Contain Pharmacologic Amounts of Lipoteichoic Acid."*** Journal of Allergy and Clinical Immunology 125(1):146-52.e1-2, 2010.

Landis, M., Yi, Q., Hyatt, A.M., Travers, A.R., Travers, J.B. ***"Involvement of P38 MAP Kinase in the Augmentation of UVB-Mediated Apoptosis via the Epidermal Platelet-Activiating Factor Receptor."*** Archives of Dermatological Research 299:263-266, 2007.

Xia, M., Salata, J.J., Figueroa, D.J., Lawlor, A.M., Liang, H.A., Liu, Y., Connolly, T.M. ***"Functional Expression of L- and T-Type Ca^{2+} Channels in Murine HL-1 Cells."*** Journal of Molecular and Cellular Cardiology 36:111-119, 2004.

Xia, M., Liu, Y., Figueroa, D.J., Chiu, C., Wei, N., Lawlor, A.M., Lu, P., Sur, C., Koblan, K.S., Connolly, T.M. ***"Characterization and Lovalization of Human Serine Racemase."*** Molecular Brain Research 125:96-104, 2004.

Posters/Abstracts

Ann-Marie Hyatt, M.D., Diya Mutasim, M.D. "Lymphocytic Macular Arteritis with Eosinophils." ASDP. 2010.

Ann-Marie Hyatt, M.D., Stephen Wolverton, M.D., Michael Kucenic, M.D. "Cutaneous Metastatic Hepatocellular Carcinoma. Gross and Microscopic Dermatology Symposium. Winter AAD. 2009.

Ann-Marie Hyatt, M.D., Lawrence Mark, M.D., PhD., Simon Warren, M.D. "Calciphylaxis Presenting Clinically as Nephrogenic Systemic Fibrosis." Gross and Microscopic Dermatology Symposium. Winter AAD. 2009.

Ann-Marie Hyatt, Megan Landis, Jeffrey Travers, Nico Mousdicas. "Impetiginized Atopic Dermatitis Lesions Contain Significant Amounts of Lipoteichoic Acid." Winter AAD. 2006.

Carrie L. Davis, M.D., Mindi M. Morris, M.D., Nicholas B. Countryman, M.D. MBA, Melanie M. Kingsley, M.D., Andrew T. Bridge M.D. MBA, **Ann-Marie Hyatt, M.D.**, Anita N. Haggstrom, M.D., Nico Mousdicas, M.D. ChB Mmed, Michael J. Kucenic, M.D., Lawrence A. Mark, M.D. PhD. "Interesting Cases from Indiana University School of Medicine." Winter AAD. 2008

Ann-Marie Hyatt, MD

Clinical Experience

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24- week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate to Severe Plaque Psoriasis. PPC-06-CD-004

An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Mutlicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated with Calcipotriene Ointment. SNA-120-202

A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients with Plaque Psoriasis: 1957-201-001

A Multicenter, Randomized, Double-Blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis: CNTO1959PSO3009

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis (ADIPSO): CAIN457AUS07

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis. B7931004

A Multicenter, Open-Label Study to assess the safety and efficacy of rIsankizuMab for maintenance in moderate to severe plaque type psoriasis. M15-997

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Efficacy of KD025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy. KD025-211

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days – DFD06-CD-005

A Multicenter Open Label Uncontrolled Study of the long term safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 16 years and 11 months of age) with mild to moderate plaque psoriasis. – RD.06.SPR.18131

Pharmacokinetics and pharmacodynamics of calcitriol 3mcg/g ointment applied twice daily for 14 days under conditions of maximal use in pediatric subjects (2 to 12 years of age) with plaque psoriasis – RD.06.SPR.18104

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis including those Previously Treated with Biologic Anti-TNFα Agent(s): CNTO1959PSA3001

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis. I4V-MC-JAIW

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with Moderate to Severe Atopic Dermatitis. B7451012

Ann-Marie Hyatt, MD

Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RVT-501 Topical Ointment in Pediatric Patients with Atopic Dermatitis. RVT-501-2007

A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Dupilumab Monotherapy In Patients ≥12 To <18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis: R668-AD-1526

A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis - 203121

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis - R668-AD-1415

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis - AN2728-AD-302

A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with Rosacea - CLS001-CO-PR-006

A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks DFD-03-CD-006

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris FX2017-22

A Phase IV Open-Label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne - ABS1517LT

A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Phase IIb Dose-Finding Study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneous Urticaria (CSU) – CQGE031C2201

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate to severe chronic hidradenitis suppurativa patients – CCJM112X2202

A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients with Chronic Idiopathic Urticaria – ML29510

A Phase III, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp KX01-AK003

Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest – LP0105-1032

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara™ (imiquimod) Cream 2.5% in Subjects with Actinic Keratoses – 094-3153-301

Ann-Marie Hyatt, MD

License/Certifications

Indiana State License #01069334A
American Board of Dermatopathology, 2011
American Board of Dermatology, 2010
ACLS Certification
CITI Certification, September 2013, February 2015, February 2016, January 2017, March 2018, March 2022